{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:56:23Z","timestamp":1781157383688,"version":"3.54.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":152,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Down syndrome regression disorder is a severe neuropsychiatric condition for which intravenous immunoglobulin offers partial benefit in many cases. The efficacy of second-line immunosuppressive therapies in those with partial responses to intravenous immunoglobulin (IVIg) remains unclear. This study sought to evaluate the comparative efficacy of B-cell depletion, Janus kinase inhibition, and mycophenolate mofetil as second-line immunosuppressive therapies in individuals with Down syndrome regression disorder. This multicenter, prospective observational cohort study included 126 individuals with Down syndrome regression disorder. Participants were aged 10\u201330 years and had demonstrated &amp;gt;50% improvement following IVIg on either the Bush-Francis Catatonia Rating Scale or the Neuropsychiatric Inventory Questionnaire, followed by second-line immunosuppression with one of three agents. Participants received B-cell depletion (rituximab or biosimilar; n = 63), Janus kinase inhibitors (tofacitinib or baricitinib; n = 34), or mycophenolate mofetil (n = 29). Treatments were assigned as part of clinical care and not randomized. The primary outcomes were change scores (\u0394) on the Bush-Francis Catatonia Rating Scale and the Neuropsychiatric Inventory Questionnaire following immunosuppression. Secondary outcomes included treatment-emergent adverse event rates. All therapies produced symptomatic improvement; however, mean \u0394 Bush-Francis Catatonia Rating Scale and \u0394 Neuropsychiatric Inventory Questionnaire scores were greatest with B-cell depletion (mean [standard deviation] \u0394 Bush-Francis Catatonia Rating Scale: \u22129.6 [4.1]; \u0394 Neuropsychiatric Inventory Questionnaire: \u221216.5 [6.1]) compared with Janus kinase inhibition (\u0394 Bush-Francis Catatonia Rating Scale: \u22126.3 [5.0]; \u0394 Neuropsychiatric Inventory Questionnaire: \u221212.0 [7.2]) and mycophenolate mofetil (\u0394 Bush-Francis Catatonia Rating Scale: \u22123.0 [4.3]; \u0394 Neuropsychiatric Inventory Questionnaire: \u22125.7 [6.8]). One-way ANOVA showed significant between-group differences for both Bush-Francis Catatonia Rating Scale (P &amp;lt; 0.001) and Neuropsychiatric Inventory Questionnaire (P &amp;lt; 0.001). Post hoc Tukey tests revealed B-cell depletion to be significantly more effective than mycophenolate mofetil on both outcomes. Adverse event rates were lowest in the B-cell depletion group (2.40\u2005events\/patient) compared with Janus kinase inhibition (3.32) and mycophenolate mofetil (4.14) (overall P &amp;lt; 0.001). In individuals with Down syndrome regression disorder who partially respond to intravenous immunoglobulin, second-line immunosuppression with B-cell depletion was associated with the greatest clinical improvement and the most favorable safety profile.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag203","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:43:12Z","timestamp":1780141392000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunosuppression in down syndrome regression disorder: a prospective observational cohort study"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D","family":"Santoro","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Children\u2019s Hospital Los Angeles , Los Angeles, CA 90027 ,","place":["USA"]},{"name":"Department of Neurology, Keck School of Medicine of the University of Southern California , Los Angeles, CA 90027 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Kazerooni","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Children\u2019s Hospital Los Angeles , Los Angeles, CA 90027 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve C","family":"Lucas","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Children\u2019s Hospital Los Angeles , Los Angeles, CA 90027 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam M","family":"Yousuf","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Children\u2019s Hospital Los Angeles , Los Angeles, CA 90027 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T","family":"Otey","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Children\u2019s Hospital Los Angeles , Los Angeles, CA 90027 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bouchard","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Children\u2019s Hospital Los Angeles , Los Angeles, CA 90027 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C","family":"Frost","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Children\u2019s Hospital Los Angeles , Los Angeles, CA 90027 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Pediatrics, Children\u2019s Hospital Los Angeles , Los Angeles, CA 90027 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhiben A","family":"Anadani","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Oklahoma Medical Center , Oklahoma City, OK 73104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asef","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Advent Health , Orlando, FL 32803 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A","family":"Manning","sequence":"additional","affiliation":[{"name":"Department of Anatomic and Clinical Pathology, Stanford University School of Medicine , Palo Alto, CA 94305 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L","family":"Rachubinski","sequence":"additional","affiliation":[{"name":"Linda Crnic Institute for Down Syndrome, Anschutz Medical Campus at the University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M","family":"Kammeyer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Anschutz Medical Campus at the University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Patel","sequence":"additional","affiliation":[{"name":"Linda Crnic Institute for Down Syndrome, Anschutz Medical Campus at the University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey E A","family":"Koster","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center and Heeren Loo Care Group , Amsterdam 1105 AZ ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnies M","family":"van Eeghen","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center and Heeren Loo Care Group , Amsterdam 1105 AZ ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi A","family":"Spinazzi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Specialized Children\u2019s Hospital , New Brunswick, NJ 08901 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Franklin","sequence":"additional","affiliation":[{"name":"Mater Research Institute, The University of Queensland , Brisbane 4101 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen A","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Toledo , Toledo, OH 43606 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9048-1941","authenticated-orcid":false,"given":"Joaquin M","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Linda Crnic Institute for Down Syndrome, Anschutz Medical Campus at the University of Colorado , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Rafii","sequence":"additional","affiliation":[{"name":"Alzheimer's Therapeutic Research Institute, University of Southern California , San Diego, CA 92121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"12","key":"2026061100564297400_fcag203-B1","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00415-020-10179-w","article-title":"Neurologic complications of down syndrome: A systematic review","volume":"268","author":"Santoro","year":"2021","journal-title":"J Neurol"},{"issue":"1","key":"2026061100564297400_fcag203-B2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.17294\/2330-0698.1875","article-title":"Prevalence of mental health conditions among 6078 individuals with down syndrome in the United States","volume":"9","author":"Rivelli","year":"2022","journal-title":"J Patient Cent Res Rev"},{"issue":"1","key":"2026061100564297400_fcag203-B3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s11689-022-09446-w","article-title":"Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder","volume":"14","author":"Santoro","year":"2022","journal-title":"J Neurodev Disord"},{"key":"2026061100564297400_fcag203-B4","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/ajmg.a.62922","article-title":"Unexplained regression in down syndrome: Management of 51 patients in an international patient database","volume":"188","author":"Santoro","year":"2022","journal-title":"Am J Med Genet A"},{"issue":"9","key":"2026061100564297400_fcag203-B5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/0883073814554654","article-title":"Down syndrome disintegrative disorder: New-onset autistic regression, dementia, and insomnia in older children and adolescents with down syndrome","volume":"30","author":"Worley","year":"2015","journal-title":"J Child Neurol"},{"issue":"6","key":"2026061100564297400_fcag203-B6","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci7060057","article-title":"Acute regression in young people with down syndrome","volume":"7","author":"Mircher","year":"2017","journal-title":"Brain Sci"},{"issue":"1","key":"2026061100564297400_fcag203-B7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13023-025-03644-0","article-title":"Caregiver burden and familial impact in down syndrome regression disorder","volume":"20","author":"Chow","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026061100564297400_fcag203-B8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41398-023-02579-z","article-title":"Immunotherapy responsiveness and risk of relapse in down syndrome regression disorder","volume":"13","author":"Santoro","year":"2023","journal-title":"Transl Psychiatry"},{"issue":"1","key":"2026061100564297400_fcag203-B9","doi-asserted-by":"crossref","first-page":"30865","DOI":"10.1038\/s41598-024-81819-8","article-title":"Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with down syndrome regression disorder","volume":"14","author":"Santoro","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"2026061100564297400_fcag203-B10","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.63524","article-title":"Safety and tolerability of intravenous immunoglobulin infusion in down syndrome regression disorder","volume":"194","author":"Santoro","year":"2024","journal-title":"Am J Med Genet A"},{"key":"2026061100564297400_fcag203-B11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/acn3.52023","article-title":"Neuroimaging abnormalities associated with immunotherapy responsiveness in down syndrome regression disorder","volume":"11","author":"Santoro","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"2026061100564297400_fcag203-B12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/dmcn.14127","article-title":"Immunotherapy in selected patients with down syndrome disintegrative disorder","volume":"61","author":"Cardinale","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"2026061100564297400_fcag203-B13","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.940175","article-title":"Assessment and diagnosis of down syndrome regression disorder: International expert consensus","volume":"13","author":"Santoro","year":"2022","journal-title":"Front Neurol"},{"issue":"2","key":"2026061100564297400_fcag203-B14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.npp.1300873","article-title":"The relative sensitivity of the clinical global impressions scale and the brief psychiatric rating scale in antipsychotic drug trials","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"2026061100564297400_fcag203-B15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578442","article-title":"JAK inhibition in down syndrome regression disorder","volume":"395","author":"Rachubinski","year":"2024","journal-title":"J Neuroimmunol"},{"issue":"9","key":"2026061100564297400_fcag203-B16","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213537","article-title":"Diagnosis and management of children with atypical neuroinflammation","volume":"104","author":"Saucier","year":"2025","journal-title":"Neurology"},{"issue":"10","key":"2026061100564297400_fcag203-B17","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3174\/ajnr.A1694","article-title":"Aicardi-goutieres syndrome: Neuroradiologic findings and follow-up","volume":"30","author":"Uggetti","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"issue":"23","key":"2026061100564297400_fcag203-B18","doi-asserted-by":"crossref","first-page":"e2368","DOI":"10.1212\/WNL.0000000000200288","article-title":"Rituximab therapy in the treatment of juvenile myasthenia gravis: The French experience","volume":"98","author":"Molimard","year":"2022","journal-title":"Neurology"},{"issue":"6","key":"2026061100564297400_fcag203-B19","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s13760-023-02329-4","article-title":"Efficacy and safety of rituximab in multiple sclerosis: A systematic review and meta-analysis","volume":"123","author":"Nabizadeh","year":"2023","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"2026061100564297400_fcag203-B20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/25785826.2024.2304364","article-title":"Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: A prospective cohort study","volume":"47","author":"Akatani","year":"2024","journal-title":"Immunol Med"},{"issue":"1","key":"2026061100564297400_fcag203-B21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: Results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"2026061100564297400_fcag203-B22","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2026061100564297400_fcag203-B23","doi-asserted-by":"crossref","first-page":"14818","DOI":"10.1038\/s41598-017-13858-3","article-title":"Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation","volume":"7","author":"Sullivan","year":"2017","journal-title":"Sci Rep"},{"issue":"48","key":"2026061100564297400_fcag203-B24","doi-asserted-by":"crossref","first-page":"24231","DOI":"10.1073\/pnas.1908129116","article-title":"Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity","volume":"116","author":"Araya","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2026061100564297400_fcag203-B25","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","article-title":"Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in down syndrome","volume":"29","author":"Waugh","year":"2019","journal-title":"Cell Rep"},{"key":"2026061100564297400_fcag203-B26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/acn3.52299","article-title":"Evidence of blood-brain barrier dysfunction and CSF immunoglobulin synthesis in down syndrome regression disorder","volume":"12","author":"Santoro","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"2026061100564297400_fcag203-B27","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.99323","article-title":"JAK inhibition decreases the autoimmune burden in down syndrome","volume":"13","author":"Rachubinski","year":"2024","journal-title":"Elife"},{"issue":"1","key":"2026061100564297400_fcag203-B28","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1038\/s41467-019-12739-9","article-title":"Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors","volume":"10","author":"Powers","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"2026061100564297400_fcag203-B29","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI129301","article-title":"Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases","volume":"130","author":"de Jesus","year":"2020","journal-title":"J Clin Invest"},{"issue":"4","key":"2026061100564297400_fcag203-B30","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1172\/JCI133737","article-title":"Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease","volume":"130","author":"Roy","year":"2020","journal-title":"J Clin Invest"},{"issue":"7","key":"2026061100564297400_fcag203-B31","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1038\/s41380-021-01065-6","article-title":"Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway","volume":"26","author":"Tripathi","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"26","key":"2026061100564297400_fcag203-B32","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg6218","article-title":"Multidimensional definition of the interferonopathy of down syndrome and its response to JAK inhibition","volume":"9","author":"Galbraith","year":"2023","journal-title":"Sci Adv"},{"key":"2026061100564297400_fcag203-B33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1110593","article-title":"Breaking down the cellular responses to type I interferon neurotoxicity in the brain","volume":"14","author":"Viengkhou","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"2026061100564297400_fcag203-B34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of type I interferons in the activation of autoreactive B cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol Cell Biol"},{"issue":"5546","key":"2026061100564297400_fcag203-B35","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1126\/science.1064890","article-title":"Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus","volume":"294","author":"Blanco","year":"2001","journal-title":"Science"},{"issue":"4","key":"2026061100564297400_fcag203-B36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/intimm\/14.4.411","article-title":"IFN-alpha\/beta enhances BCR-dependent B cell responses","volume":"14","author":"Braun","year":"2002","journal-title":"Int Immunol"},{"issue":"7951","key":"2026061100564297400_fcag203-B37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41586-023-05736-y","article-title":"Autoimmunity in down's syndrome via cytokines, CD4 T cells and CD11c(+) B cells","volume":"615","author":"Malle","year":"2023","journal-title":"Nature"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag203\/68455593\/fcag203.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/3\/fcag203\/68455593\/fcag203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/3\/fcag203\/68455593\/fcag203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:56:55Z","timestamp":1781153815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag203\/8700151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag203","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag203"}}